Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — ESG Presentation (November 2024)
36 slides from Kyowa Kirin's sustainability presentation, Nov 26, 2024
Slide 1: Kyowa Kirin Sustainability Meeting
Kyowa Kirin Sustainability Meeting Kyowa Kirin’s initiatives for realizing a sustainable society and its business November 26, 2024
Slide 2: Forward-looking statements
This document contains certain forward‐looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward‐looking statements are based upon information available to the company at the present time and upon reasona
Slide 3: Agenda
Agenda Representative Director of the Board, 1. Kyowa Kirin’s Sustainability President and CEO Masashi Miyamoto Representative Director of the Board, 2. Story for Vision 2030 & Value Creation Story President and CEO Masashi Miyamoto 3. Provide pharmaceuticals for unmet medical needs & Address patien
Slide 4: Kyowa Kirin's Sustainability
Kyowa Kirin’s Sustainability 4 © Kyowa Kirin Co., Ltd.
Slide 5: Kyowa Kirin's Sustainability
Kyowa Kirin's Sustainability The sustainability of the Kyowa Kirin Group means to co-create life-changing value with social stakeholders to make people (facing illness) smile. We will achieve both social sustainability and our own sustainability through realizing our vision. The promotion of sustain
Slide 6: Story for Vision 2030 & Value Creation Story
Story for Vision 2030 & Value Creation Story 6 © Kyowa Kirin Co., Ltd.
Slide 7: Management Philosophy and Core Values
Management Philosophy and Core Values Transform lives with passion and excitement. Our Philosophy Challenge the status quo in all of our work. Core Values The Kyowa Kirin Group companies strive to contribute to the health and well- being of people around the world by creating new value through the p
Slide 8: Our Vision toward 2030
Vision Provide pharmaceuticals for Our Vision toward 2030 unmet medical needs We are focused on developing medicines Kyowa Kirin will realize the successful for diseases where there is a clear patient creation and delivery of life-changing need for new options. We make full use value that ultimately
Slide 9: Strategy to Realize our New Vision
Strategy to Realize our New Vision ⚫ Maximize the value of global products ⚫ Launch services that go beyond pharmaceuticals ⚫ Establish framework to ensure stable global supplies ⚫ Foster a corporate culture suited to global business ⚫ Build a drug pipeline to drive growth beyond 2025 development Pr
Slide 10: Strategies for creating and delivering life-changing value - Story for Vision 2030
Strategies for creating and delivering life-changing value - Story for Vision 2030 In the midst of major environmental changes, we formulated the Story for Vision 2030 to further ensure the realization of our vision. While increasing the resolution of the vision, we will link strategies and issues m
Slide 11: Delivering Life-changing Value as a GSP: Materiality
Delivering Life-changing Value as a GSP Materiality Kyowa Kirin has selected materiality (key management issues) to realize its vision for 2030, creating a clearer link between our vision and business strategy. Going forward, the whole Group will continue to work as one to achieve our vision for 203
Slide 12: Value Creation Story
Value Creation Story In order to make people facing illness smile, we will create social and economic value by utilizing our human and intellectual capital, which are the source of our competitiveness, and by ensuring that all employees prioritize patient centricity, and by creating value together w
Slide 13: Provide pharmaceuticals for unmet medical needs & Address patient-centric healthcare needs
Provide pharmaceuticals for unmet medical needs & Address patient-centric healthcare needs 13 © Kyowa Kirin Co., Ltd.
Slide 14: Story for Vision 2030: Strategies for creating and delivering life-changing value
Provide pharmaceuticals for unmet medical needs & Address patient-centric healthcare needs Story for Vision 2030 Strategies for creating and delivering C life-changing value A Value delivery on Disease Science our own Assets in focus disease areas Life-changing B Collabora- tive value Drug Discovery
Slide 15: Orchard Therapeutics, Hematopoietic Stem Cell Gene Therapy
Provide pharmaceuticals for unmet medical needs Orchard Therapeutics the Value of , Hematopoietic Stem Cell Gene Therapy ⚫Hematopoietic stem cell gene therapy（HSC-GT）; approach for inherited diseases and rare diseases ⚫Libmeldy®/LenmeldyTM — challenge for cure for under-served diseases. ⚫Create nov
Slide 16: Deliver Libmeldy/Lenmeldy to More Patients
Address patient-centric healthcare needs Deliver Libmeldy®/LenmeldyTM to More Patients ⚫Importance of expanding Newborn Screening (NBS) for delivering HSC-GT to more patients and more effectively. ⚫Orchard proceeds collaboration with governments and academic assosiations to ensure that MLD is added
Slide 17: Awareness Activities for Rare Diseases
Address patient-centric healthcare needs Awareness Activities for Rare Diseases Delivering the Value of Crysvita to XLH Patients Worldwide XLH : X-linked Hypophosphatemia Discovering Thorough Providing Extensive Insights in Surveys for opportunities to Information Presentation of 10 Abstracts on Res
Slide 18: Awareness Activities for Rare Diseases
Address patient-centric healthcare needs Awareness Activities for Rare Diseases CTCL Time to Act Rare Disease Month （February） • Rare Cancer: CTCL (Cutaneous T Reflecting on People Living with Rare Diseases and Aiming Cell Lymphoma) for Increased Awareness • Symptoms may resemble skin • Relay messag
Slide 19: Strategic Partnering
Provide pharmaceuticals for unmet medical needs Strategic Partnering rocatinlimab Amgen and Kyowa Kirin ⚫ Global Ph 3 clinical trials are in progress for moderate to severe atopic dermatitis ⚫ Amgen: 40-Year Collaboration Since the Early Days of Our Pharmaceutical Business. Launched six products pr
Slide 20: Collaboration in Drug Discovery: 35-Year Partnership with La Jolla Institute
Collaboration in Drug Discovery: 35-Year Partnership with La Jolla Institute ⚫ 1988: Supporting the Establishment of La Jolla Institute for Allergy & Immunology – The Origin of Our Immunology and Allergy Research La Jolla Institute Initiatives ⚫ Structural analysis of therapeutic molecules and immun
Slide 21: Talent management strategy for realizing our Vision
Talent management strategy for realizing our Vison Story for Vision 2030 & talent management strategy / Talent development for creating life-changing value –Research division- 21 © Kyowa Kirin Co., Ltd.
Slide 22: The Ideal Way to Realize the Growth Story 2030
The Ideal Way to Realize the Growth Story 2030 Get the dots (HR actions) mutually connected to maximize HR contribution to the KK enterprise business strategy “Story for 2030” to create Life-changing values Contribute to Strategy Execution from People Aspect Story for Vision 2030 Vision 2030 Life- (
Slide 23: Linking Business Strategy to HR Strategy
Linking Business Strategy to HR Strategy Talent-development & -management under new HR strategy to contribute to “Story for Vision 2030” to deliver Life-changing Value Cores of HR Strategy 1 Unlock Individual Potential: Create a thriving workplace where individuals are energized and empowered to do
Slide 24: Developing our High Potential Talent – OKK Academy
Developing our High Potential Talent – OKK Academy Global and Regional HR teams collaborate to focus on the development and identification of next-generation leadership talent to ensure a strong foundation for the future of Kyowa Kirin Develop next Successor Candidate OKK Global Leadership Program(O
Slide 25: Challenge for Realizing Story for Vision 2030 and Novel Drug Discovery Model
Challenge for Realizing “Story for Vision 2030” and Establishment Novel Drug Discovery Model ⚫ To ensure the success of our new challenges, we have established four key pillars Pursuing expertise as a global pioneer, we create and deliver life-changing value as a Japan-based Global Pharmaceutical Co
Slide 26: Globalization of Research Organization
Globalization of Research Organization ⚫Transition to a global organization structure (Global Research Organization, "GRO") in January 2025 to promote consolidation of expertise and resources through collaboration of drug discovery engines in Japan, the U.S., and the U.K. ◼ Establish a trans-regiona
Slide 27: Realizing the Successful Creation and Delivery of Life-changing Value
Realizing the Successful Creation and Delivery of Life-changing Value ⚫ Proceeding “Transition to GRO” and “Pursuing Research OPEX” transforms our business operation Image of Work Style that Maximizes Human Capital Utilization Multinationalization of Outsourcing of routine tasks Collaboration with e
Slide 28: Overall DX Human Resource Strategy
Overall DX Human Resource Strategy ⚫Recruit leaders to plan and execute each research DX initiative & upskill digital literacy across the company Recruitment of highly skilled Upskilling across professionals the company Clarify the requirements (necessary skills & no. of people) & appropriately comb
Slide 29: ESG updates
Appendix ESG updates 29 © Kyowa Kirin Co., Ltd.
Slide 30: Scope3 Compliance
Initiatives for a Sustainable Society Reduce global environmental impact Scope 3 compliance (working with suppliers) Scope1+2: Promote renewable energy switching ⚫ Formulation of Scope3 reduction targets : 30% reduction by CO₂ emissions: 64% reduction expected (from 2019) 2030 (from 2019) and roadma
Slide 31: Environmental Preservation Highlights: From the 2023 Integrated Report
Environmental Preservation Highlights: From the 2023 Integrated Report Addressing climate change Biodiversity Forestry activities to preserve water resources ⚫ For Details; Integrated Report 31 © Kyowa Kirin Co., Ltd.
Slide 32: Decent Governance System as a Listed Subsidiary
Decent Governance System as a Listed Subsidiary ⚫ Decision-making process ⚫“Securing management independence” and -> Ensuring that independent outside directors are in the “Reasonable cooperation to maintain listing” majority -> An independent outside director elected as chairperson -> Clearly state
Slide 33: Governance Highlights: From the 2023 Integrated Report
Governance Highlights: From the 2023 Integrated Report Basic Policy on Corporate Governance Based on our philosophy that states that “The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in
Slide 34: Governance Highlights: From the 2023 Integrated Report
Governance Highlights: From the 2023 Integrated Report Board Members with a Wide Array of Skills The Board of Directors comprises diverse individuals with various skills (knowledge, experience, etc.). This is to enable the Board of Directors to fulfill its decision- making and management oversight f
Slide 35: Governance Highlights: From the 2023 Integrated Report
Governance Highlights: From the 2023 Integrated Report Evaluation of the Board of Directors’ Effectiveness ⚫ For Details; Integrated Report To identify gaps between expected roles and responsibilities of the Board of Directors set forth in the “Kyowa Kirin Corporate Governance Policy” and the actual
Slide 36: Kyowa Kirin
CsyOWa KIRIN